Doxorubicin, as an anthracycline antibiotic, has an anti-tumor effect mainly through interfering with topoisomerase II (TOP2A) activity by interacting with DNA, but in recent years it has been found to bind to specific proteins and exert an anti-tumor effect through non-DNA targeting mechanisms (Olbryt et al., 2017). The gene discussed is TOP2A; the disease is neoplasm.